SCHEMBL3205916

SCHEMBL3205916

CC#Cc1cc([N+](=O)[O-])n([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TYMS P04818 1/20 0.43
POLB P06746 2/20 0.41
POLA1 P09884 1/20 0.40
POLD1 P28340 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16085986 0.90 TYMS (0.42) TYMSPOLBPOLA1POLD1
SCHEMBL16086184 0.85 TYMS (0.38) TYMSPOLBPOLA1POLD1
SCHEMBL1032503 0.84 POLB (0.42) POLBPOLA1POLD1
SCHEMBL16086287 0.84 TYMS (0.39) TYMSPOLBPOLA1POLD1
SCHEMBL16104239 0.83 TYMS (0.36) TYMSPOLB
SCHEMBL14979297 0.83 TYMS (0.36) TYMSPOLB
SCHEMBL16675570 0.83 TYMS (0.36) TYMSPOLB
SCHEMBL2498542 0.81 TK1 (0.42)
SCHEMBL2495405 0.79 TYMS (0.47) TYMSPOLB
SCHEMBL16681938 0.78 TYMS (0.35) TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2781599-B1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2019-05-08 EP disclosed
US-9873879-B2 Nucleic acid fragment binding to target protein TAGCYX BIOTECHNOLOGIES (JP) 2018-01-23 US disclosed
US-20170073683-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2017-03-16 US disclosed
US-9540650-B2 Nucleic acid fragment binding to target protein TAGCYX BIOTECHNOLOGIES (JP) 2017-01-10 US disclosed
US-20150119254-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2015-04-30 US disclosed
EP-2781599-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN Riken (JP) 2014-09-24 EP disclosed
EP-1970445-B1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS RIKEN (JP) 2012-09-26 EP disclosed
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS RIKEN (JP) 2010-02-11 US disclosed
EP-1970445-A1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS Riken (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119254-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TARBP1, DNTT, FABP1 TYMS 558/4885POLB 245/4885POLA1 298/4885
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS POLM, POLL, POLRMT TYMS 36/4885POLB 8/4885POLA1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.